Veterans and Servicemembers PTSD Emerging Treatment Review Act of 2026
Latest action: Referred to the House Committee on Armed Services. (2026-06-30)
View the official record →In plain English
What this bill does
This bill would require the Department of Defense to produce a single report for Congress on an emerging, investigational treatment for treatment-resistant PTSD, specifically a 2026 clinical trial using whole-mushroom psilocybin. The report would assess the trial's safety, dosing, and feasibility data, how it might apply to servicemembers and veterans, and what legal, regulatory, and logistical steps would be involved in any future research or access. It directs a study and report only; it does not itself authorize any new treatment or program.
Who it affects
It would most directly affect active-duty servicemembers, National Guard and reserve members, and veterans who have PTSD that hasn't responded to existing treatments. It also involves Defense Department health officials, who would have to prepare the report.
Key points
- Requires the Assistant Secretary of Defense for Health Affairs to submit a report to Congress within 180 days of enactment.
- The report focuses on data from a specific 2026 Phase 1 clinical trial of whole psilocybin-containing mushrooms for PTSD.
- It must cover safety, dosing, adverse events, force readiness, suicide prevention, continuity of care between military and VA facilities, and legal/regulatory requirements (including FDA and DEA coordination).
- It must assess 'Right to Try' pathways and estimate the resources, workforce, infrastructure, and timeline for possible pilot activities or research starting in fiscal year 2027.
- The bill orders a study and report; it does not by itself create a new treatment program, authorize use of psilocybin, or change existing drug laws.
Plain-English summary generated by AI from the official record. Neutral by design; verify against the official text linked above.
Ask Versed about this bill
Versed reads the full bill and answers in plain English. Nonpartisan.
Ask anything about what this bill does, who it affects, or the case for and against it. Versed answers only from the bill text and tells you when something isn't in the bill.
Versed explains; it never tells you how to vote. Answers come from the bill text and may be incomplete. Verify against the official record.
Make your voice count
Email your representatives
Register where you stand in two clicks. We draft the note; you edit and send. Your position is tallied so reps can be held to account.
Be the first to tell your representatives where you stand on this.
1 · Your position
If you support this
Supporting this bill means requiring the Defense Department to study and report to Congress on an emerging psilocybin-based PTSD treatment and what future research or access would involve.
If you oppose this
Opposing this bill means declining to require that report, leaving the Defense Department without this specific mandate to evaluate the psilocybin trial data for servicemembers and veterans.
2 · How strongly
3 · Choose your representatives
Your address is used once to find your districts and is never stored.
Add your full address above to find the people who represent you.
4 · Your details
5 · Your message